Standout Papers
Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection
2017
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
2013 StandoutScience
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Chagas disease
2010 Standout
Abacavir Hypersensitivity Reaction after Switching from the Twice-Daily to the Once-Daily Formulation
2007
HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina
2013
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
2009
Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS
2007
Triglycerides and Cardiovascular Disease
2011
Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150,95
2013
Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials
2010
Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada
2010
Global health burden and needs of transgender populations: a review
2016 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Elevated Pre–Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection
2017 StandoutNobel
Coinfection With HIV-1 and HCV—A One-Two Punch
2009
When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries
2011
Periluminal Distribution of HIV-Binding Target Cells and Gp340 in the Oral, Cervical and Sigmoid/Rectal Mucosae: A Mapping Study
2015 StandoutNobel
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
2011 Standout
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Population biological principles of drug-resistance evolution in infectious diseases
2011
Cardiovascular implications from untreated human immunodeficiency virus infection
2011
Differences in Human Immunodeficiency Virus Care and Treatment Among Subpopulations in the United States
2013
A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease
2011 StandoutNobel
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals
2012
HLA-B*5701 Screening for Hypersensitivity to Abacavir
2008 Standout
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
2011
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
2008 Standout
Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations
2007
HIV prevention among youth: A randomized controlled trial of voluntary counseling and testing for HIV and male condom distribution in rural Kenya
2019 StandoutNobel
Emtricitabine (FTC) for the treatment of HIV infection
2004
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans
2008 StandoutNobel
Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children
2016 Standout
Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance
2006
Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors
2015 StandoutNobel
Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome
2015 StandoutNobel
Treatment for Adult HIV Infection
2006
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
2009
Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy
2008
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
2016
Emtricitabine
2005
Understanding the mechanisms and drivers of antimicrobial resistance
2015 Standout
Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group
2002
Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti
2010
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
2009
The end of AIDS: HIV infection as a chronic disease
2013 Standout
Management of the metabolic effects of HIV and HIV drugs
2011
Midwifery and quality care: findings from a new evidence-informed framework for maternal and newborn care
2014 Standout
Tipranavir
2008
New first and second generation inhibitors of human immunodeficiency virus-1 integrase
2011
Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate
2009
Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) Naïve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission
2014
Tipranavir: a novel protease inhibitor for HIV therapy
2009
The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial
2002
Global epidemiology of HIV infection in men who have sex with men
2012 Standout
Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
2010
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
2006
What We Talk About When We Talk About Fat
2014 Standout
HIV and Aging: Time for a New Paradigm
2010
Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy
2010
A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase
2018 StandoutNobel
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Sex differences in immune responses
2016 Standout
The CD4 lymphocyte count and risk of clinical progression
2006
Computational design of orthogonal nucleoside kinases
2010 StandoutNobel
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
2008
Population-based HIV-1 incidence in France, 2003–08: a modelling analysis
2010
Early Mortality in Adults Initiating Antiretroviral Therapy (ART) in Low- and Middle-Income Countries (LMIC): A Systematic Review and Meta-Analysis
2011
Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe
2010
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome
2006
Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco
2010
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
2010 StandoutNobel
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
2015 Standout
Evaluation of antiretrovirals in animal models of HIV infection
2009
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial
2013 Standout
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Rating evidence in treatment guidelines
2013
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Therapeutic drug monitoring of antiretrovirals for people with HIV
2009
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
2009
Molecular Evolution of Antifungal Drug Resistance
2017
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women
2010
Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010
2010
The Future of HIV Microbicides: Challenges and Opportunities
2009
Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles
2013
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study
2012
Antimicrobial resistance of Staphylococcus aureus: genetic basis
1987
Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 1. Molecular Design and Establishment of an Advanced Two-Metal Binding Pharmacophore
2012
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
2018 StandoutScience
The oral mucosa immune environment and oral transmission of HIV /SIV
2013
Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis
2006
The Crisis in Antibiotic Resistance
1992 StandoutScience
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Trifluoromethyltrimethylsilane: Nucleophilic Trifluoromethylation and Beyond
2014
Proteases and protease inhibitors in infectious diseases
2017
Reference Ranges for Lymphocyte Subsets among Healthy Hong Kong Chinese Adults by Single-Platform Flow Cytometry
2013
From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of Pyrazoles
2011 Standout
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
2013
Emerging Concepts in the Immunopathogenesis of AIDS
2008
2015 update of the drug resistance mutations in HIV-1
2015
CF2H, a Hydrogen Bond Donor
2017 Standout
HIV Testing and Risky Sexual Behaviour
2014
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Works of Pedro Cahn being referenced
Hepatitis B Virus Genotype Distribution and Its Lamivudine-Resistant Mutants in HIV-Coinfected Patients with Chronic and Occult Hepatitis B
2007
Factors associated with healthcare avoidance among transgender women in Argentina
2014
MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro
2014
Time to act: global apathy towards HIV/AIDS is a crime against humanity
2002
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
2007
Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults
2008
Antiretroviral Treatment of Adult HIV Infection
2010
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
2011
Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients
2006
Antiretroviral Treatment of Adult HIV Infection
2008
Cerebral tumor-like American trypanosomiasis in acquired immunodeficiency syndrome
1999
Antiretroviral Drugs for Preventing Mother-to-Child Transmission of HIV: A Review of Potential Effects on HIV-Exposed but Uninfected Children
2011
Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial
2003
Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS
2000
Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth
2006
A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin‐2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus–Infected Patients with CD4+Cell Counts ⩾350/mm3
2000
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects
2003
Prevalence of hepatitis viruses in an anti‐human immunodeficiency virus‐positive population from Argentina. Amulticentre study
1999
Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults
2005
HLA-Driven Convergence of HIV-1 Viral Subtypes B and F Toward the Adaptation to Immune Responses in Human Populations
2008
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
2003
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
2006
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy
2000
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
2004
Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean
2009
O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance
2008
Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina
2001
Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding
2008
Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings
2010
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy
2004
Tuberculosis and HIV: A Partnership Against the Most Vulnerable
2003
Etravirine in treatment‐experienced, HIV ‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study
2014
Antiretroviral Treatment of Adult HIV Infection
2014
G484S Amino Acid Substitution in Lanosterol 14-α Demethylase ( ERG11 ) Is Related to Fluconazole Resistance in a Recurrent Cryptococcus neoformans Clinical Isolate
2003
The Immunomodulatory Nutritional Intervention NR100157 Reduced CD4+ T-Cell Decline and Immune Activation: A 1-Year Multicenter Randomized Controlled Double-Blind Trial in HIV-Infected Persons Not Receiving Antiretroviral Therapy (The BITE Study)
2013
An outbreak of multiply resistant Staphylococcus aureus in Buenos Aires. Clinical observations and plasmid pattern analysis.
1984
Magnitude, Breadth, and Functional Profile of T-Cell Responses during Human Immunodeficiency Virus Primary Infection with B and BF Viral Variants
2008
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society–USA Panel
2020
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates
1995